OrganiGram (OGI)
(Delayed Data from NSDQ)
$1.47 USD
-0.07 (-4.55%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.46 -0.01 (-0.68%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OGI 1.47 -0.07(-4.55%)
Will OGI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OGI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OGI
Are Medical Stocks Lagging OrganiGram (OGI) This Year?
Why OrganiGram (OGI) Might Surprise This Earnings Season
OGI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Other News for OGI
Organigram's Promising Results From Nanoemulsion Technology Study To Improve Cannabis Edibles
Cannabis Stock Movers For August 8, 2024
Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
Organigram’s Nanoemulsion Tech Revolutionizes Cannabis Consumption
IM Cannabis, Organigram And Other Hot Cannabis Stocks Soon To Report Earnings, What Investors Need To Know Now